All News

Making cannabidiol water-soluble could reduce dissolution and food-related variability, but improved aqueous behavior has not yet been shown to produce better clinical outcomes.

Jennifer Griffin, PharmD, MS, discusses how pharmacists' accessibility and trust position them to fight vaccine misinformation and help close a coming gap in health care access as physician shortages loom.

The FDA's decision makes iberdomide the first approved CELMoD for patients with relapsed/refractory multiple myeloma.

This study strengthens the evidence base supporting current guidelines and may help reverse the recent decline in pediatric antiviral use.

Active surveillance increased from 27% in 2005 to 93% in 2024, reflecting a major shift away from immediate treatment for favorable-risk disease.

Modeling in Canada suggests price drops of up to 70% could make dual glucagon-like peptide-1 (GLP-1) RA/SGLT2 inhibitor therapy the preferred strategy for high-risk patients with type 2 diabetes (T2D).

When a PA is incomplete or missing the right documentation, the rejection lands at the pharmacy counter, not the prescriber's desk.

The warning has prompted new CDC recommendations for prevention and molecular diagnostic testing.

Most medically complex adults can be vaccinated, but determining when and with which product may require additional assessment.

Andrew Bzowyckyj, PharmD, explains how the CKM framework turns albuminuria, ejection fraction, and inflammation into patient-specific risk stratification.

Inlexzo (gemcitabine intravesical system) reshapes NMIBC care: bladder‑dwelling therapy, J9183 billing, and coordinated pharmacy‑urology safety steps.

The combination also produced a 78.6% complete response rate in heavily pretreated patients with R/R mantle cell lymphoma following BTK inhibitor therapy.

There are specific, appropriate uses of AI that support pharmacy students and residents without compromising the integrity of their own work.

Pharmacy's location-based title reflects an unfinished professional transition that provider status and privileging, not renaming, must complete.

mRNA vaccines are just one of several vaccine platforms available to patients.

Robust reporting and analysis of medication errors allows health care institutions to identify systemic vulnerabilities, revamp workflows, and build a resilient infrastructure.

Timed clinician prompts plus patient reminders boost annual LDCT follow-up to 75%, highlighting workflow fixes that close lung cancer screening gaps.

From double-dipping GLP-1s to off-label pioglitazone, Susan Cornell, PharmD, breaks down where the metabolic dysfunction-associated steatotic liver disease (MASLD) drug evidence stands today.

Phase 3 MajesTEC-9 findings show teclistamab monotherapy significantly improves progression-free survival and overall survival compared with PVd or Kd.

Though COVID-19 is responsible for fewer deaths and less disease burden, it still represents a formidable threat among seasonal respiratory infections.

Pharmacists can educate patients on preventive measures to avoid heat-related illnesses.

Educate patients about psoriasis pharmacotherapy options and monitor for medication adherence

The designation highlights an emerging strategy targeting TNFR2-mediated immune suppression in heavily pretreated platinum-resistant ovarian cancer.

Early trial data suggest zongertinib shrinks HER2‑mutant NSCLC brain metastases, highlighting CNS control and pharmacist guidance.

IRA reshapes Medicare drug costs: Part B negotiations loom, pharmacies adapt, and patients gain Part D caps—see impacts on oncology care and access.

New recommendations move noncore shots to shared clinical decision-making, but a court stay keeps day-to-day pharmacy practice unchanged.

A phase 4 study found that a suzetrigine-based multimodal pain regimen provided favorable postoperative pain control, with 76.1% of patients recovering without opioid rescue medication.

A first-in-class RNA degrader targeting MYC mRNA showed preclinical antimyeloma activity, offering a potential new strategy for targeting a historically difficult-to-drug driver of multiple myeloma.